Compliance Rate

Compliance Rate 48.0%
Compliant submissions 48
Incompliant submissions 52
Total trials 100

Your Clinical Trials

Showing 539600 of 542236 entries
View as:

STRONG Program for Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05649969 Org: User:
Start: 12/01/22 End: 07/31/25 Due: 07/31/26

Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies

Phase: N/A Priority: Normal
NCT ID: NCT04783597 Org: User:
Start: 07/12/21 End: 01/31/27 Due: 01/31/28

EKO SENSORA: Detecting Clinically Significant Murmurs

Phase: N/A Priority: Normal
NCT ID: NCT06155643 Org: User:
Start: 10/26/23 End: 07/26/25 Due: 07/26/26

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase: N/A Priority: Normal
NCT ID: NCT02495233 Org: User:
Start: 09/08/15 End: 09/28/16 Due: 09/28/17

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04232553 Org: User:
Start: 06/22/20 End: 12/31/26 Due: 12/31/27

Treatment of Non-Anemic Iron Deficiency in Pregnancy

Phase: N/A Priority: Normal
NCT ID: NCT05423249 Org: User:
Start: 08/12/22 End: 11/15/24 Due: 11/15/25

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04214249 Org: User:
Start: 02/17/21 End: 01/30/26 Due: 01/30/27

Impact of Erythropoietin on Hematological Adaptations and Physical Performance

Phase: N/A Priority: Normal
NCT ID: NCT05078138 Org: User:
Start: 09/01/21 End: 04/01/23 Due: 04/01/24

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06378047 Org: User:
Start: 04/10/24 End: 04/30/27 Due: 04/30/28

Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04922723 Org: User:
Start: 10/03/22 End: 02/28/26 Due: 02/28/27

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Phase: N/A Priority: Normal
NCT ID: NCT05745532 Org: User:
Start: 12/01/20 End: 12/30/25 Due: 12/30/26

LEGION Hinge Safety and Efficacy Study

Phase: N/A Priority: Normal
NCT ID: NCT02445443 Org: User:
Start: 06/30/15 End: 08/01/28 Due: 08/01/29

A Mobile Health Intervention to Achieve Appropriate Gestational Weight Gain in Overweight/Obese Women

Phase: N/A Priority: Normal
NCT ID: NCT03880461 Org: User:
Start: 01/21/21 End: 03/31/25 Due: 03/31/26

Acute Porphyria Biomarkers for Disease Activity

Phase: N/A Priority: Normal
NCT ID: NCT02935400 Org: User:
Start: 04/28/14 End: 12/31/26 Due: 12/31/27

Inclusion Appeal Videos and Intent to Register for Pediatric Clinical Trials

Phase: N/A Priority: Normal
NCT ID: NCT06138145 Org: User:
Start: 11/17/22 End: 08/29/23 Due: 08/29/24

Novel Robotic Prostatectomy Technique for Early Urinary Continence

Phase: N/A Priority: Normal
NCT ID: NCT06237114 Org: User:
Start: 03/08/24 End: 04/10/25 Due: 04/10/26

Serial Echocardiography After Subarachnoid Hemorrhage

Phase: N/A Priority: Normal
NCT ID: NCT00123695 Org: User:
Start: 05/31/05 End: 06/30/08 Due: 06/30/09

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

Phase: N/A Priority: Normal
NCT ID: NCT00625495 Org: User:
Start: 09/30/02 End: 11/30/02 Due: 11/30/03

Human Oral Detection of Glucose Olygomers

Phase: N/A Priority: Normal
NCT ID: NCT02589353 Org: User:
Start: 04/21/17 End: 02/16/23 Due: 02/16/24

Assessment of Risk in Chronic Airways Disease Evaluation

Phase: N/A Priority: Normal
NCT ID: NCT01656421 Org: User:
Start: 05/31/11 End: 04/30/19 Due: 04/30/20

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT04607148 Org: User:
Start: 11/16/20 End: 11/14/22 Due: 11/14/23

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Phase: N/A Priority: Normal
NCT ID: NCT04442269 Org: User:
Start: 09/15/20 End: 02/09/24 Due: 02/09/25

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Phase: N/A Priority: Normal
NCT ID: NCT05111509 Org: User:
Start: 08/22/22 End: 12/31/25 Due: 12/31/26

Humectant Activity of a New Formulation of Gynomunal® Vaginalgel

Phase: N/A Priority: Normal
NCT ID: NCT01948583 Org: User:
Start: 05/31/13 End: 07/31/13 Due: 07/31/14

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Phase: N/A Priority: Normal
NCT ID: NCT06621199 Org: User:
Start: 07/08/24 End: 12/31/27 Due: 12/31/28